This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change MDGLNegative Net Change
biotechs earnings-preview medical pharmaceuticals
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
TEVANegative Net Change ANIPNegative Net Change ADPTNegative Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alterity (ATHE) Up on Interim Data From Advance MSA Study
by Zacks Equity Research
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
CGENPositive Net Change ATHEPositive Net Change XAIRNegative Net Change TRDANegative Net Change
biotechs
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
RHHBYPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
LXRXNegative Net Change SAVANegative Net Change LXEOPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
BAYRYNegative Net Change ANIPNegative Net Change ADPTNegative Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
ANIPNegative Net Change RARENegative Net Change ADPTNegative Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
RHHBYPositive Net Change ABBVNegative Net Change ANIPNegative Net Change
biotechs
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
JNJNegative Net Change BAYRYNegative Net Change ORICPositive Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
by Zacks Equity Research
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
AZNPositive Net Change LLYNegative Net Change LXRXNegative Net Change
biotechs medical pharmaceuticals
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
ANIPNegative Net Change ADPTNegative Net Change RAPTPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
RHHBYPositive Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.
ANIPNegative Net Change ADPTNegative Net Change RAPTPositive Net Change LSTANegative Net Change
biotechs
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
by Zacks Equity Research
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
BEAMNegative Net Change ANIPNegative Net Change ADPTNegative Net Change RAPTPositive Net Change
biotechs
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
CORTPositive Net Change NTLANegative Net Change TRDANegative Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
by Supriyo Bose
United Therapeutics (UTHR), ABB (ABBNY), Lockheed Martin (LMT), MPLX (MPLX) and Banco de Chile (BCH) are some of the stocks with high ROE to profit from as easing inflationary pressures ignite rate cut hopes.
LMTPositive Net Change UTHRNegative Net Change BCHNegative Net Change MPLXPositive Net Change ABBNYPositive Net Change
aerospace biofuels biotechs finance oil-energy tech-stocks
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
NVSPositive Net Change INCYPositive Net Change CORTPositive Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
by Zacks Equity Research
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.
ADPTNegative Net Change VSTMNegative Net Change RAPTPositive Net Change ACRVNegative Net Change
biotechs
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
BIIBPositive Net Change NVOPositive Net Change LLYNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
BMYNegative Net Change JNJNegative Net Change LEGNPositive Net Change
biotechs cell-therapy medical pharmaceuticals
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
MRKNegative Net Change IMMPNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Fennec (FENC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fennec (FENC) stock based on the movements in the options market lately.
FENCPositive Net Change
biotechnology biotechs medical